These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 15339850)

  • 1. Possible roles for activating RAS mutations in the MGUS to MM transition and in the intramedullary to extramedullary transition in some plasma cell tumors.
    Rasmussen T; Kuehl M; Lodahl M; Johnsen HE; Dahl IM
    Blood; 2005 Jan; 105(1):317-23. PubMed ID: 15339850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. From MGUS to Multiple Myeloma, a Paradigm for Clonal Evolution of Premalignant Cells.
    van Nieuwenhuijzen N; Spaan I; Raymakers R; Peperzak V
    Cancer Res; 2018 May; 78(10):2449-2456. PubMed ID: 29703720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma.
    Chng WJ; Huang GF; Chung TH; Ng SB; Gonzalez-Paz N; Troska-Price T; Mulligan G; Chesi M; Bergsagel PL; Fonseca R
    Leukemia; 2011 Jun; 25(6):1026-35. PubMed ID: 21468039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Occurrence of dysregulated oncogenes in primary plasma cells representing consecutive stages of myeloma pathogenesis: indications for different disease entities.
    Rasmussen T; Theilgaard-Mönch K; Hudlebusch HR; Lodahl M; Johnsen HE; Dahl IM
    Br J Haematol; 2003 Oct; 123(2):253-62. PubMed ID: 14531906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Comprehensive Review of the Genomics of Multiple Myeloma: Evolutionary Trajectories, Gene Expression Profiling, and Emerging Therapeutics.
    Awada H; Thapa B; Awada H; Dong J; Gurnari C; Hari P; Dhakal B
    Cells; 2021 Aug; 10(8):. PubMed ID: 34440730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma.
    Mikulasova A; Wardell CP; Murison A; Boyle EM; Jackson GH; Smetana J; Kufova Z; Pour L; Sandecka V; Almasi M; Vsianska P; Gregora E; Kuglik P; Hajek R; Davies FE; Morgan GJ; Walker BA
    Haematologica; 2017 Sep; 102(9):1617-1625. PubMed ID: 28550183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular and biologic markers of progression in monoclonal gammopathy of undetermined significance to multiple myeloma.
    Mailankody S; Mena E; Yuan CM; Balakumaran A; Kuehl WM; Landgren O
    Leuk Lymphoma; 2010 Dec; 51(12):2159-70. PubMed ID: 20958231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone marrow fibroblasts overexpress miR-27b and miR-214 in step with multiple myeloma progression, dependent on tumour cell-derived exosomes.
    Frassanito MA; Desantis V; Di Marzo L; Craparotta I; Beltrame L; Marchini S; Annese T; Visino F; Arciuli M; Saltarella I; Lamanuzzi A; Solimando AG; Nico B; De Angelis M; Racanelli V; Mariggiò MA; Chiacchio R; Pizzuti M; Gallone A; Fumarulo R; D'Incalci M; Vacca A
    J Pathol; 2019 Feb; 247(2):241-253. PubMed ID: 30357841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of a dominantly inherited hyperphosphorylated paraprotein target with sporadic and familial multiple myeloma and monoclonal gammopathy of undetermined significance: a case-control study.
    Grass S; Preuss KD; Ahlgrimm M; Fadle N; Regitz E; Pfoehler C; Murawski N; Pfreundschuh M
    Lancet Oncol; 2009 Oct; 10(10):950-6. PubMed ID: 19767238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    Cesana C; Klersy C; Barbarano L; Nosari AM; Crugnola M; Pungolino E; Gargantini L; Granata S; Valentini M; Morra E
    J Clin Oncol; 2002 Mar; 20(6):1625-34. PubMed ID: 11896113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular pathogenesis and a consequent classification of multiple myeloma.
    Bergsagel PL; Kuehl WM
    J Clin Oncol; 2005 Sep; 23(26):6333-8. PubMed ID: 16155016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular Pathogenesis of Multiple Myeloma: Clinical Implications.
    Maura F; Bergsagel PL
    Hematol Oncol Clin North Am; 2024 Apr; 38(2):267-279. PubMed ID: 38199896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FOXP1 expression in monoclonal gammopathy of undetermined significance and multiple myeloma.
    Korać P; Peran I; Skrtić A; Ajduković R; Kristo DR; Dominis M
    Pathol Int; 2009 May; 59(5):354-8. PubMed ID: 19432679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contributions of the Bone Microenvironment to Monoclonal Gammopathy of Undetermined Significance Pathogenesis.
    Gámez B; Edwards CM
    Curr Osteoporos Rep; 2018 Dec; 16(6):635-641. PubMed ID: 30229522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathway-based network analysis of myeloma tumors: monoclonal gammopathy of unknown significance, smoldering multiple myeloma, and multiple myeloma.
    Dong L; Chen CY; Ning B; Xu DL; Gao JH; Wang LL; Yan SY; Cheng S
    Genet Mol Res; 2015 Aug; 14(3):9571-84. PubMed ID: 26345890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of progression in monoclonal gammopathy of undetermined significance.
    Rajkumar SV
    Clin Cancer Res; 2009 Sep; 15(18):5606-8. PubMed ID: 19737944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncogene-induced senescence: a potential breakpoint mechanism against malignant transformation in plasma cell disorders.
    Lehners N; Ellert E; Xu J; Hillengass J; Leichsenring J; Stenzinger A; Goldschmidt H; Andrulis M; Raab MS
    Leuk Lymphoma; 2018 Nov; 59(11):2660-2669. PubMed ID: 29616856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N- and K-ras oncogenes in plasma cell dyscrasias.
    Corradini P; Ladetto M; Inghirami G; Boccadoro M; Pileri A
    Leuk Lymphoma; 1994 Sep; 15(1-2):17-20. PubMed ID: 7858496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subclonal evolution in disease progression from MGUS/SMM to multiple myeloma is characterised by clonal stability.
    Dutta AK; Fink JL; Grady JP; Morgan GJ; Mullighan CG; To LB; Hewett DR; Zannettino ACW
    Leukemia; 2019 Feb; 33(2):457-468. PubMed ID: 30046162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Chromosomal abnormalities and clonal evolution in multiple myeloma].
    Ishida T
    Rinsho Ketsueki; 2014 Oct; 55(10):2036-45. PubMed ID: 25297769
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.